BUZZ-Spruce Biosciences soars after FDA's 'breakthrough therapy' tag for genetic disorder drug
Reuters
Oct 06
BUZZ-<a href="https://laohu8.com/S/SPRB">Spruce Biosciences</a> soars after FDA's 'breakthrough therapy' tag for genetic disorder drug
** Shares of Spruce Biosciences SPRB.O rise 69% to $14.89 premarket
** Co says U.S. FDA grants "breakthrough therapy" tag for its experimental drug, tralesinidase alfa, to treat Sanfilippo Syndrome Type B
** The condition is a genetic disorder that causes progressive brain damage in children
** The breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need
** Co plans to submit application for U.S. approval in Q1 of 2026
** As of last close, stock down 72% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.